520 related articles for article (PubMed ID: 25024322)
21. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.
Le Bastard N; Aerts L; Sleegers K; Martin JJ; Van Broeckhoven C; De Deyn PP; Engelborghs S
J Alzheimers Dis; 2013; 33(3):807-22. PubMed ID: 23034521
[TBL] [Abstract][Full Text] [Related]
22. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.
Wang L; Gao T; Cai T; Li K; Zheng P; Liu J;
Neurosci Lett; 2020 Jan; 715():134658. PubMed ID: 31794792
[TBL] [Abstract][Full Text] [Related]
24. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.
Morenas-Rodríguez E; Alcolea D; Suárez-Calvet M; Muñoz-Llahuna L; Vilaplana E; Sala I; Subirana A; Querol-Vilaseca M; Carmona-Iragui M; Illán-Gala I; Ribosa-Nogué R; Blesa R; Haass C; Fortea J; Lleó A
Sci Rep; 2019 May; 9(1):7803. PubMed ID: 31127154
[TBL] [Abstract][Full Text] [Related]
25. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
Kettunen P; Larsson S; Holmgren S; Olsson S; Minthon L; Zetterberg H; Blennow K; Nilsson S; Sjölander A
J Alzheimers Dis; 2015; 44(4):1313-22. PubMed ID: 25420549
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
27. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
29. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
30. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
[TBL] [Abstract][Full Text] [Related]
31. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
33. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
[TBL] [Abstract][Full Text] [Related]
34. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.
Gispert JD; Monté GC; Falcon C; Tucholka A; Rojas S; Sánchez-Valle R; Antonell A; Lladó A; Rami L; Molinuevo JL
Neurobiol Aging; 2016 Feb; 38():47-55. PubMed ID: 26827642
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases.
Baldacci F; Lista S; Cavedo E; Bonuccelli U; Hampel H
Expert Rev Proteomics; 2017 Apr; 14(4):285-299. PubMed ID: 28281838
[TBL] [Abstract][Full Text] [Related]
36. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
Fortea J; Vilaplana E; Alcolea D; Carmona-Iragui M; Sánchez-Saudinos MB; Sala I; Antón-Aguirre S; González S; Medrano S; Pegueroles J; Morenas E; Clarimón J; Blesa R; Lleó A;
Ann Neurol; 2014 Aug; 76(2):223-30. PubMed ID: 24852682
[TBL] [Abstract][Full Text] [Related]
38. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
39. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.
Alcolea D; Irwin DJ; Illán-Gala I; Muñoz L; Clarimón J; McMillan CT; Fortea J; Blesa R; Lee EB; Trojanowski JQ; Grossman M; Lleó A
J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):180-186. PubMed ID: 30297518
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.
Pan C; Korff A; Galasko D; Ginghina C; Peskind E; Li G; Quinn J; Montine TJ; Cain K; Shi M; Zhang J
J Alzheimers Dis; 2015; 45(3):709-19. PubMed ID: 25613100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]